Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Biofourmis
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedPrivately held
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Feb 2026: Biofourmis's former CEO, who left in Aug 2023, was reported to have been charged in Singapore with falsifying company invoices to inflate revenue; the charges are unproven. CopilotIQ acquired Biofourmis in Oct 2024.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Biofourmis found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
No product recalls, FDA safety notices or warning letters involving Biofourmis found in HSH's search of the last 24 months.
Contract performance
No notable contract go-lives, terminations or customer disputes involving Biofourmis found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.